129 related articles for article (PubMed ID: 10520807)
1. The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions.
Mathew V; Grill DE; Scott CG; Grantham JA; Ting HH; Garratt KN; Holmes DR
J Am Coll Cardiol; 1999 Oct; 34(4):1163-9. PubMed ID: 10520807
[TBL] [Abstract][Full Text] [Related]
2. Effect of abciximab on late adverse events in patients with diabetes mellitus undergoing stent implantation.
Velianou JL; Mathew V; Wilson SH; Barsness GW; Grill DE; Holmes DR
Am J Cardiol; 2000 Nov; 86(10):1063-8. PubMed ID: 11074200
[TBL] [Abstract][Full Text] [Related]
3. Treatment of saphenous vein bypass grafts with ultrasound thrombolysis: a randomized study (ATLAS).
Singh M; Rosenschein U; Ho KK; Berger PB; Kuntz R; Holmes DR
Circulation; 2003 May; 107(18):2331-6. PubMed ID: 12732601
[TBL] [Abstract][Full Text] [Related]
4. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.
Mak KH; Challapalli R; Eisenberg MJ; Anderson KM; Califf RM; Topol EJ
Am J Cardiol; 1997 Oct; 80(8):985-8. PubMed ID: 9352964
[TBL] [Abstract][Full Text] [Related]
5. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ
Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997
[TBL] [Abstract][Full Text] [Related]
6. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial.
van den Brand M; Laarman GJ; Steg PG; De Scheerder I; Heyndrickx G; Beatt K; Kootstra J; Simoons ML
Eur Heart J; 1999 Nov; 20(21):1572-8. PubMed ID: 10529325
[TBL] [Abstract][Full Text] [Related]
7. Influence of procedural success on immediate and long-term clinical outcome of patients undergoing percutaneous revascularization of occluded coronary artery bypass vein grafts.
Berger PB; Bell MR; Grill DE; Simari R; Reeder G; Holmes DR
J Am Coll Cardiol; 1996 Dec; 28(7):1732-7. PubMed ID: 8962559
[TBL] [Abstract][Full Text] [Related]
8. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction.
Neumann FJ; Kastrati A; Schmitt C; Blasini R; Hadamitzky M; Mehilli J; Gawaz M; Schleef M; Seyfarth M; Dirschinger J; Schömig A
J Am Coll Cardiol; 2000 Mar; 35(4):915-21. PubMed ID: 10732888
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes following "rescue" administration of abciximab in patients undergoing percutaneous coronary angioplasty.
Fuchs S; Kornowski R; Mehran R; Gruberg L; Satler LF; Pichard AD; Kent KM; Stone GW; Leon MB
J Invasive Cardiol; 2000 Oct; 12(10):497-501. PubMed ID: 11022207
[TBL] [Abstract][Full Text] [Related]
10. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.
Lincoff AM; Califf RM; Anderson KM; Weisman HF; Aguirre FV; Kleiman NS; Harrington RA; Topol EJ
J Am Coll Cardiol; 1997 Jul; 30(1):149-56. PubMed ID: 9207636
[TBL] [Abstract][Full Text] [Related]
11. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up.
Montalescot G; Antoniucci D; Kastrati A; Neumann FJ; Borentain M; Migliorini A; Boutron C; Collet JP; Vicaut E
Eur Heart J; 2007 Feb; 28(4):443-9. PubMed ID: 17251257
[TBL] [Abstract][Full Text] [Related]
12. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
[TBL] [Abstract][Full Text] [Related]
13. [Does abciximab improve the prognosis of diabetics after percutaneous coronary intervention?].
Hernández García JM; Domínguez Franco A; Jiménez-Navarro MF; Alonso Briales JH; Curiel Balsera E; Gómez Doblas JJ; De Teresa Galván E
Rev Esp Cardiol; 2002 Aug; 55(8):810-5. PubMed ID: 12199976
[TBL] [Abstract][Full Text] [Related]
14. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.
Marso SP; Lincoff AM; Ellis SG; Bhatt DL; Tanguay JF; Kleiman NS; Hammoud T; Booth JE; Sapp SK; Topol EJ
Circulation; 1999 Dec 21-28; 100(25):2477-84. PubMed ID: 10604884
[TBL] [Abstract][Full Text] [Related]
16. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty.
Wöhrle J; Grebe OC; Nusser T; Al-Khayer E; Schaible S; Kochs M; Hombach V; Höher M
Circulation; 2003 Apr; 107(14):1840-3. PubMed ID: 12682003
[TBL] [Abstract][Full Text] [Related]
17. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial.
Mehilli J; Kastrati A; Schulz S; Früngel S; Nekolla SG; Moshage W; Dotzer F; Huber K; Pache J; Dirschinger J; Seyfarth M; Martinoff S; Schwaiger M; Schömig A;
Circulation; 2009 Apr; 119(14):1933-40. PubMed ID: 19332467
[TBL] [Abstract][Full Text] [Related]
18. Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?).
Kalyanasundaram A; Blankenship JC; Berger P; Herrmann H; McClure R; Moliterno D
Catheter Cardiovasc Interv; 2007 Apr; 69(5):623-9. PubMed ID: 17192960
[TBL] [Abstract][Full Text] [Related]
19. Clinical and angiographic results of transluminal extraction coronary atherectomy in saphenous vein bypass grafts.
Safian RD; Grines CL; May MA; Lichtenberg A; Juran N; Schreiber TL; Pavlides G; Meany TB; Savas V; O'Neill WW
Circulation; 1994 Jan; 89(1):302-12. PubMed ID: 8281662
[TBL] [Abstract][Full Text] [Related]
20. Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts.
Barsness GW; Buller C; Ohman EM; Schechter E; Pucillo A; Taylor MA; Miller MJ; Reiner JS; Churchill D; Chandler AB; Gonzalez M; Smith J; Tommaso C; Berdan LG; Wildermann NM; Hasdai D; Holmes DR
Am Heart J; 2000 May; 139(5):824-9. PubMed ID: 10783216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
